|Korea and U.S. Joint Research Team Establishes New Genomic Subtypes of Liver Cancer|
|Date||Modified Date : 2022.06.16|
Korea and U.S. Joint Research Team Establishes New Genomic Subtypes of Liver Cancer
HCC has various clinical features, and treatment can vary from one patient to another. Therefore, it is crucial to accurately identify the features of each patient's cancer to determine most relevant treatment. Currently, various classifications of HCC are available, but none of them are easy to use in clinical settings.
Integrating 16 existing genomic signatures for HCC subtypes, the research team established a new classification system of five subtypes - STM, CIN, IMH, BCM, and DLP - based on mRNA expressions.
The classification of the subtypes systematically divided patient groups into those with poor prognostic features based on stem cell characteristics and those with a high-level of immune activity who are more likely to respond to immunotherapy. This is expected to help provide customized treatment for each HCC patient.
Professor Sun-young Yim from Korea University Anam Hospital said, "Many universities and research institutes participated in this large-scale study and we will continue to define markers that may predict treatment response in liver cancer patients."
Professor Kang from the Division of Colorectal Surgery at Korea University Guro Hospital said, "There are increasing number of treatment options and I hope that this system can help physicians to provide individualized treatment."
The study was published in the March 2022 online edition of Hepatology. Professors Kang, Yim, and Lee were listed in the biographical dictionary called 'Hanbitsa' in which researchers who have conducted influential research are listed.